Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy.

Wamalwa DC, Lehman DA, Benki-Nugent S, Gasper MA, Gichohi R, Maleche-Obimbo E, Farquhar C, John-Stewart GC, Overbaugh J.

J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):267-74. doi: 10.1097/QAI.0b013e31827b4ac8.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.

Chang LW, Harris J, Humphreys E.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008494. doi: 10.1002/14651858.CD008494. Review.

PMID:
20393969
4.

Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.

Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S49-56. doi: 10.1093/infdis/jit107. Review.

5.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
6.

Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure.

Rutherford GW, Anglemyer A, Easterbrook PJ, Horvath T, Vitoria M, Penazzato M, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S161-9. doi: 10.1097/QAD.0000000000000236. Review.

PMID:
24849476
7.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.

Collins SE, Grant PM, Shafer RW.

Drugs. 2016 Jan;76(1):75-98. doi: 10.1007/s40265-015-0515-6. Review.

8.
9.

HIV treatment adherence, drug resistance, virologic failure: evolving concepts.

Nachega JB, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, Mills EJ, Gross R.

Infect Disord Drug Targets. 2011 Apr;11(2):167-74. Review.

10.

Defining treatment failure in resource-rich settings.

Aldous JL, Haubrich RH.

Curr Opin HIV AIDS. 2009 Nov;4(6):459-66. doi: 10.1097/COH.0b013e328331dea5. Review.

11.

Approach to the treatment-experienced patient.

Gallant JE.

Curr HIV/AIDS Rep. 2005 Jun;2(2):83-9. Review.

PMID:
16091253
12.

Human Immunodeficiency Virus.

Armstrong WS, Guarner J, Kraft CS, Caliendo AM.

Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.DMIH2-0024-2015. Review.

PMID:
27726785
13.

Adherence-resistance relationships to combination HIV antiretroviral therapy.

Bangsberg DR, Kroetz DL, Deeks SG.

Curr HIV/AIDS Rep. 2007 May;4(2):65-72. Review.

PMID:
17547827
14.

Recent advances in research of HIV infection: implications of viral and host genetics on treatment and prevention.

Haaland RE, Johnson JA, Tang J.

Public Health Genomics. 2013;16(1-2):31-6. doi: 10.1159/000345935. Epub 2013 Mar 18. Review.

15.

[Usefulness of antiretroviral resistance tests in the clinical practice].

Soriano Vázquez V, de Mendoza C, Gallego Donoso O, Valer López-Fando L, González-Lahoz J.

Rev Clin Esp. 2001 Sep;201(9):508-12. Review. Spanish. No abstract available.

PMID:
11692405

Supplemental Content

Support Center